Morphosys AG (MORG.DE)
23 Dec 2014
|Market Cap (Mil.):||€2,017.16|
|Shares Outstanding (Mil.):||26.44|
FRANKFURT, Dec 22 - Morphosys AG on Monday said it had received a payment from Novartis in connection with the initiation of a phase 1 clinical trial of a HuCAL antibody in the field of oncology.
* Breast cancer study fails to prove added Kadcyla benefit
* Says mor208 program receives positive opinion for orphan medicinal product designation from EMA for DLBCL
* Announced promising clinical data on its proprietary drug candidate mor208 from a phase 2a study
FRANKFURT, Oct 23 - German biotech company Morphosys raised its earnings forecast for 2014, citing a milestone payment from Janssen Biotech as well as a partial shift of development costs to 2015.
* Says acquires Lanthipeptide Technology from Lanthio Pharma Source text for Eikon: Further company coverage:
July 28 - Shares in Morphosys AG rise 2.6 percent at open after Q2 results
July 28 - Morphosys AG : * Says H1 revenues from continuing operations were EUR 30.5 million (H1 2013:
Earnings vs. Estimates
Analyst Research Reports
Provider: Directors Deals Ltd.
Morphosys AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
Provider: Thomson Reuters StreetEvents
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.